
New phone system at TWINCORE
Some extension numbers have changed.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.

Some extension numbers have changed.

zukunft.niedersachsen provides €2.7 million in funding for joint project on rare diseases

€100,000 from the German Society for Parkinson's Disease and Movement Disorders
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Mayer L, Arnold J, Roettele F, Reuter N, Pattekar A, Ohtani T, Ribeiro M, Siwicki R, Bruder K, Obwegs D, Stahl E, Buechel S, Roehlen N, Kolter J, Mansoori Moghadam Z, Alaswad A, Zhumalidova Z, Li G, Liu X, Li Y, Singh A, Villacorta Hidalgo J, Paraskevopoulou M, Yajnik V, Juarez J, Ren Y, Li H, Wherry E, Lewis J, Wu G, Bewtra M, Tomov V, Thimme R, Bengsch B, Hasselblatt P, Picelli S, Hofmann M, Sagar
Ilan S, Bartsch Y, Jung W, Kliuchnikov E, Roy V, Bonifer R, Walker-Sperling V, Borducchi E, Nkolola J, Lauffenburger D, Stieh D, Barouch D, Julg B
Koeken V, Nissen T, Birk N, Boahen C, van Crevel R, Kumar V, Li Y, Aaby P, Benn C, Netea M
The project investigates how HCMV is recognized by the immune system and which mechanisms the virus uses to camouflage itself. The aim is to understand the immune reactions and develop therapies for severely affected patients.
The project is developing iPSC-based therapies for MSMD patients, a genetic disease with mutations in the IFN-γ signaling pathway that lead to severe mycobacterial infections. The aim is to improve the treatment prognosis.
Older people are at high risk of a poor immune response to the flu vaccine. Together with partners, we are looking for biomarkers and risk factors for this inadequate response and are investigating ways to improve the vaccination response.
We are investigating how antibodies protect against HCV infection, in particular what properties they have during a healing infection. The aim is to identify antibodies that are important for an effective vaccine against HCV.

